步长制药(603858.SH)：上半年净利润6.28亿元，同比增长85.55%

Core Viewpoint - The company reported significant growth in both revenue and net profit for the first half of 2025, driven by increased sales and reduced production costs [1] Financial Performance - The company achieved operating revenue of 5.664 billion yuan, a year-on-year increase of 4.27% [1] - Net profit attributable to shareholders reached 628 million yuan, reflecting a substantial year-on-year growth of 85.55% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 619 million yuan, marking a remarkable year-on-year increase of 180.04% [1] - Basic earnings per share were reported at 0.5934 yuan [1] Dividend Distribution - The company plans to distribute a cash dividend of 3.90 yuan (including tax) for every 10 shares to all shareholders [1] Operational Insights - The significant increase in total profit, net profit, and earnings per share compared to the same period last year was primarily due to the growth in drug sales, a decrease in production costs, and the amortization of valuation increments from acquisitions of Tonghua Guhong Pharmaceutical and Jilin Tiancai Pharmaceutical, which will be fully amortized by the end of 2024 [1] - The net cash flow from operating activities saw a substantial increase compared to the same period last year, mainly due to a reduction in cash payments related to operating activities [1]